TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Clarity Pharmaceuticals Ltd. ( (AU:CU6) ) has provided an announcement.
Clarity Pharmaceuticals has confirmed that its US-based manufacturing operations will remain unaffected by the upcoming 100% tariff on imported branded pharmaceuticals in the US. By maintaining a fully integrated supply chain within the US, Clarity aims to ensure uninterrupted progress of its clinical trials and commercialization efforts, reinforcing its commitment to the US market and its strategy to deliver innovative cancer treatments.
The most recent analyst rating on (AU:CU6) stock is a Buy with a A$5.70 price target. To see the full list of analyst forecasts on Clarity Pharmaceuticals Ltd. stock, see the AU:CU6 Stock Forecast page.
More about Clarity Pharmaceuticals Ltd.
Clarity Pharmaceuticals is a clinical-stage radiopharmaceutical company focused on developing innovative treatments for serious diseases, particularly cancer. The company specializes in Targeted Copper Theranostics using its SAR Technology Platform.
Average Trading Volume: 3,317,991
Technical Sentiment Signal: Buy
Current Market Cap: A$1.32B
Find detailed analytics on CU6 stock on TipRanks’ Stock Analysis page.